Inventory and quantitative assessment of geosites and geodiversity sites: a review

"Published online: 15 January 2015"The inventory and quantitative assessment of the most valuable occurrences of geodiversity are essential steps in any geoconservation strategy and in the establishment of priorities in site management. Despite the existence of many site inventories applied to different scales (countries, municipalities, parks, etc.), the criteria used for their selection are often unclear and poorly defined. This paper proposes a new approach to the concepts of geosite and geodiversity site and reviews the procedures used in the development of a systematic site inventory applied to different scales and values. Procedures to achieve a numerical evaluation of the value and degradation risk of sites are reviewed and new criteria are proposed. Finally, guidelines are presented, bearing in mind the preparation of effective geodiversity inventories, to support geoparks’ strategies. This paper aims to contribute to a better understanding and use of the above-mentioned concepts, which are essential for the implementation of geoconservation actions worldwide.The author thanks Diamantino Pereira, Flavia Lima, and Paulo Pereira for fruitful discussions and insights; Teresa Mota for the English revision; and the reviewers for significant improvements of the first submitted version. This paper results of the research done at the University of Minho and at the Geology Centre of the University of Porto, partially founded by the Foundation for Science and Technology (Portugal), strategic project with reference PEst-OE/CTE/UI0039/2014

Neuroprotective effects on microglia and insights into the structure–activity relationship of an antioxidant peptide isolated from Pelophylax perezi

© 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly citedTryptophyllins constitute a heterogeneous group of peptides that are one of the first classes of peptides identified from amphibian's skin secretions. Here, we report the structural characterization and antioxidant properties of a novel tryptophyllin-like peptide, named PpT-2, isolated from the Iberian green frog Pelophylax perezi. The skin secretion of P. perezi was obtained by electrical stimulation and fractionated using RP-HPLC. De novo peptide sequencing was conducted using MALDI MS/MS. The primary structure of PpT-2 (FPWLLS-NH2 ) was confirmed by Edman degradation and subsequently investigated using in silico tools. PpT-2 shared physicochemical properties with other well-known antioxidants. To test PpT-2 for antioxidant activity in vitro, the peptide was synthesized by solid phase and assessed in the chemical-based ABTS and DPPH scavenging assays. Then, a flow cytometry experiment was conducted to assess PpT-2 antioxidant activity in oxidatively challenged murine microglial cells. As predicted by the in silico analyses, PpT-2 scavenged free radicals in vitro and suppressed the generation of reactive species in PMA-stimulated BV-2 microglia cells. We further explored possible bioactivities of PpT-2 against prostate cancer cells and bacteria, against which the peptide exerted a moderate antiproliferative effect and negligible antimicrobial activity. The biocompatibility of PpT-2 was evaluated in cytotoxicity assays and in vivo toxicity with Galleria mellonella. No toxicity was detected in cells treated with up to 512 µg/ml and in G. mellonella treated with up to 40 mg/kg PpT-2. This novel peptide, PpT-2, stands as a promising peptide with potential therapeutic and biotechnological applications, mainly for the treatment/prevention of neurodegenerative disorders.This work was financed by FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalization (POCI), and by Portuguese funds through FCT - Fundação para a Ciência e a Tecnologia in the framework of the project POCI-01-0145-FEDER-031158 – PTDC/BII-BIO/31158/2017. The authors would like to thank the participation and scientific support of the Unit projects UIDB/50006/2020 | UIDP/50006/2020, and the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Universal Faixa ‘B’ (grant number 32103/2018-0). A.P. is a recipient of a post-doctoral grant from the project PTDC/BII-BIO/31158/2017. The authors would like to thank the researcher Roberto Resendes (CiBio, University of the Azores, Ponta Delgada, São Miguel, Azores, Portugal) for the logistical support in the collection of samples. C.P.A acknowledges FCT-MCTES fellowship PD/BD/136860/2018. A.B.-N. and F.C.D.A.L. acknowledge CNPq (grants 420449/2018-3 and 428211/2018-6) for financial support.info:eu-repo/semantics/publishedVersio

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the 'preclinical' stage (pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive impairment. Developing and judiciously administering such therapies will require biomarker panels to identify early AD pathology, classify disease stage, monitor pathological progression, and predict cognitive decline. To discover such biomarkers, we measured AD-associated changes in the cerebrospinal fluid (CSF) proteome.CSF samples from individuals with mild AD (Clinical Dementia Rating [CDR] 1) (n = 24) and cognitively normal controls (CDR 0) (n = 24) were subjected to two-dimensional difference-in-gel electrophoresis. Within 119 differentially-abundant gel features, mass spectrometry (LC-MS/MS) identified 47 proteins. For validation, eleven proteins were re-evaluated by enzyme-linked immunosorbent assays (ELISA). Six of these assays (NrCAM, YKL-40, chromogranin A, carnosinase I, transthyretin, cystatin C) distinguished CDR 1 and CDR 0 groups and were subsequently applied (with tau, p-tau181 and Aβ42 ELISAs) to a larger independent cohort (n = 292) that included individuals with very mild dementia (CDR 0.5). Receiver-operating characteristic curve analyses using stepwise logistic regression yielded optimal biomarker combinations to distinguish CDR 0 from CDR>0 (tau, YKL-40, NrCAM) and CDR 1 from CDR<1 (tau, chromogranin A, carnosinase I) with areas under the curve of 0.90 (0.85-0.94 95% confidence interval [CI]) and 0.88 (0.81-0.94 CI), respectively.Four novel CSF biomarkers for AD (NrCAM, YKL-40, chromogranin A, carnosinase I) can improve the diagnostic accuracy of Aβ42 and tau. Together, these six markers describe six clinicopathological stages from cognitive normalcy to mild dementia, including stages defined by increased risk of cognitive decline. Such a panel might improve clinical trial efficiency by guiding subject enrollment and monitoring disease progression. Further studies will be required to validate this panel and evaluate its potential for distinguishing AD from other dementing conditions

Morfologia social e contextualização topográfica: a micro-história de Edoardo Grendi

Il saggio prende in considerazione il ruolo di Edoardo Grendi nella teorizzazione della proposta microstorica italiana, generalmente sconosciuto o sottostimato nel panorama accademico sudamericano

Preparation of highly porous nitrogen-doped biochar derived from birch tree wastes with superior dye removal performance

Abstract Heteroatom doping is a highly effective strategy that can be used to modify carbonaceous adsorbents to improve their chemical reactivity and increase their adsorptive properties. Herein, a simple method is reported for the preparation of nitrogen-doped biochar using a natural and abundant biowaste from birch trees and melamine as a nitrogen dopant for the adsorption of Acid red 18 (AR-18) dye from water. The doped biochars were also characterized for their performance during the treatment of synthetic effluents. The physicochemical characterization results showed that the N-doping process provoked remarkable chances on the biochar morphology, pore structure, and surface functionalities. N-doped biochar showed abundant nitrogen functional groups with 5.4 % of N in its structure while non-doped carbon showed traces with 0.47 %. Moreover, the specific surface area of doped biochar was dominated by mesopores (86.4 %) while non-doped was dominated by micropores (67.8 %). Raman analysis showed that the incorporation of N created more defects in the biochar structure. The adsorption experiments showed that the N-doping boosted the biochar adsorptive performance. The maximum adsorption capacity of the doped biochar was 545.2 mgg−1, while the non-doped exhibited 444.5 mgg−1, i.e., an increase of 22.6 %. The kinetic and equilibrium studies showed that Avrami fractional order and Liu models were the most suitable for describing the experimental AR-18 dye adsorption data. The equilibrium parameters were found to obey a nonlinear relationship with the temperature. Since the biochars are highly porous, pore filling was the main adsorption mechanism, however; AR-18 dye removal suggests that interactions such as electrostatic, hydrogen bonds, Lewis acid-base, and π-π between the adsorbent and the dye are involved. The thermodynamic studies showed that the removal of the AR-18 dye from the solution is dependent on temperature, exothermic, and spontaneous. The N-doped biochar showed excellent removal performances of contaminants from synthetic effluents confirming their high efficiency for color removal. This research shows that N-doping is an efficient strategy to design effective, low-cost, and sustainable adsorbents to remediate dye contamination in wastewater

Synthesis of novel mesoporous selenium-doped biochar with high-performance sodium diclofenac and reactive orange 16 dye removals

Abstract In this study, for the first time, a selenium-doped mesoporous biochar was prepared and efficiently employed for sodium diclofenac and reactive orange 16 dye adsorption. The characterization results indicated that selenium doping had a remarkable impact on Biochar-Se morphological and physicochemical structures. The efficacy of developed biochar samples on reactive orange 16 (RO-16) and diclofenac (DCF) removals was fully investigated. For both molecules (DCF and RO-16), Liu’s equilibrium model offered the best fitness with maximum adsorption capacity values of 355 mg g−1 for DCF and 538 mg g−1 for RO-16 for Biochar-Se. Multiple mechanisms including pore filling, π-π interaction, and hydrogen bonding between the Biochar-Se and DCF/RO-16 molecules were involved in the adsorption process. Se-nanoparticles formed metal–oxygen bonds, which boosted the adsorption of DCF and RO-16 molecules. The current work offered a feasible approach for the development of Se-doped biochar adsorbent that is incredibly effective in treating wastewater

Sustainable supercapacitors based on polypyrrole-doped activated biochar from wood waste electrodes

Abstract The synthesis of high-performance carbon-based materials from biomass residues for electrodes has been considered a challenge to achieve in supercapacitor-based production. In this work, activated biochar has been prepared as the active electrode material for supercapacitors (SCs), and an effective method has been explored to boost its capacitive performance by employing polypyrrole (PPy) as a biochar dopant. The results for physicochemical characterization data have demonstrated that PPy doping affects the biochar morphology, specific surface area, pore structure, and incorporation of surface functionalities on modified biochar. Biochar-PPy exhibited a surface area of 87 m² g−1, while pristine biochar exhibited 1052 m² g−1. The SCs were assembled employing two electrodes sandwiched with PVA solid-state film electrolyte as a separator. The device was characterized by standard electrochemical assays that indicated an improvement of 34% in areal capacitance. The wood electrodes delivered high areal capacitances of 282 and 370 mF cm−2 at 5 mA cm−2, for pure biochar and biochar doped with PPy, respectively, with typical retention in the capacitive response of 72% at the end of 1000 cycles of operation of the supercapacitor at high current density, indicating that biochar-PPy-based electrode devices exhibited a higher energy density when compared to pure biochar devices